NEVVI Medicare utilization intelligence
or

← back

Provider profile

GOODYEAR, SARAH MD

Hematology-Oncology · NPI 1891728622 · SELLERSVILLE, PA

1
Groups
51
Codes · 2024
143,651
Disclosed services

GOODYEAR, SARAH is a Hematology-Oncology in SELLERSVILLE, PA, a member of 1 medical group, who billed 51 distinct codes to Medicare Part B in 2024.

Groups: ALLIANCE CANCER SPECIALISTS P.C. (LANGHORNE, PA)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

143,651
disclosed services
51
codes billed to Medicare Part B
Prior year · CY2023 121,012 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1453 Injection, fosaprepitant, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J1449 Injection, eflapegrastim-xnst, 0.1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9267 Injection, paclitaxel, 1 mg
J0897 Injection, denosumab, 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
J2469 Injection, palonosetron hcl, 25 mcg
J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
J0640 Injection, leucovorin calcium, per 50 mg
J1626 Injection, granisetron hydrochloride, 100 mcg
96375 Injection of additional new drug or substance into vein
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J9190 Injection, fluorouracil, 500 mg
J9045 Injection, carboplatin, 50 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
36415 Insertion of needle into vein for collection of blood sample
96372 Injection of drug or substance under skin or into muscle
96413 Administration of chemotherapy into vein, 1 hour or less
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
J1200 Injection, diphenhydramine hcl, up to 50 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
J3490 Unclassified drugs
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96411 Administration of additional new drug or substance into vein using push technique
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
99221 Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes
J7030 Infusion, normal saline solution , 1000 cc
96523 Irrigation of implanted venous access drug delivery device
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96361 Infusion into a vein for hydration, each additional hour
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
96360 Infusion into a vein for hydration, 31-60 minutes
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.